A Phase-2 Pilot Study of a Therapeutic Combination of Δ < sup > 9 < /sup > -Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette's Syndrome

CONCLUSIONS: Although the initial data from this trial in adults with refractory Tourette's syndrome are promising, future randomized double-blind placebo-controlled trials are necessary to demonstrate efficacy of THX-110 treatment. The challenges raised by the difficulty in blinding trials due to the psychoactive properties of many cannabis-derived compounds need to be further appreciated in these trial designs.PMID:34340527 | DOI:10.1176/appi.neuropsych.19080178
Source: Journal of Neuropsychiatry and Clinical Neurosciences - Category: Psychiatry Authors: Source Type: research